Antimicrobial resistance remains a critical global health concern, necessitating the investigation of alternative therapeutic approaches. With the diminished efficacy of conventional small molecule drugs due to the emergence of highly resilient bacterial strains, there is growing interest in the potential for alternative therapeutic modalities. As naturally occurring viruses of bacteria, bacteriophage (or phage) are being re-envisioned as a platform to engineer properties that can be tailored to target specific bacterial strains and employ diverse antibacterial mechanisms. However, limited understanding of key pharmacological properties of phage is a major challenge to translating its use from preclinical to clinical settings. Here, this work reviews modern advancements in phage-based antimicrobial therapy and discusses the in vivo pharmacokinetics and biodistribution of phage, addressing critical challenges in their application that must be overcome for successful clinical implementation.

中文翻译：

---

噬菌体的药代动力学和生物分布及其在抗菌治疗中的应用

抗生素耐药性仍然是一个重要的全球健康问题，因此需要研究替代治疗方法。由于高复原力细菌菌株的出现，传统小分子药物的疗效逐渐减弱，人们对替代治疗方式的潜力越来越感兴趣。作为天然存在的细菌病毒，噬菌体（或噬菌体）被重新设想为一个设计特性的平台，可以针对特定细菌菌株进行定制并采用不同的抗菌机制。然而，对噬菌体关键药理学特性的了解有限是将其用途从临床前转化为临床的主要挑战。在这里，这项工作回顾了基于噬菌体的抗菌疗法的现代进展，并讨论了噬菌体的体内药代动力学和生物分布，解决了其应用中必须克服的关键挑战，以成功进行临床实施。